ACH-SITAGLIPTIN: May exceed established acceptable intake limit for NTTP.
Brand(s)
Last updated
Summary
Product
ACH-SITAGLIPTIN
Issue
Health products - Product safety
What to do
Consult your health care professional if you have any health concerns.
Affected products
| Brand | Product Name | Market Authorization | Dosage Form | Strength | Lot |
|---|---|---|---|---|---|
| ACH-SITAGLIPTIN | ACH-SITAGLIPTIN | DIN 02512475 | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE) 25 MG | P2206573 |
| ACH-SITAGLIPTIN | ACH-SITAGLIPTIN | DIN 02512483 | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE) 50 MG | P2206574 |
| ACH-SITAGLIPTIN | ACH-SITAGLIPTIN | DIN 02512491 | Tablet | SITAGLIPTIN (SITAGLIPTIN PHOSPHATE) 100 MG | P2206575, P2206981 |
Issue
The affected lots may exceed the established acceptable intake limit for 7-nitroso-3-(trifluoromethyl)- 5,6,7,8-tetrahydro[1,2,4] triazolo-[4,3-a]pyrazine (NTTP).
What you should do
- Verify if your product is affected.
- Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
- Contact the recalling firm if you have any questions about the recall.
- Report any health product related side effects to Health Canada.
- Report any other health product safety complaints to Health Canada.
Additional information
Background
Depth of recall: Retailers
Details
Original published date:
Alert / recall type
Health product recall
Category
Health products - Drugs
Companies
Accord Healthcare Inc.
3535 Boulevard St-Charles, Suite 704,
Kirkland, QC
H9H 5B9
Published by
Health Canada
Audience
General public
Healthcare
Industry
Recall class
Type I
Identification number
RA-75915
Get notified
Receive notifications for new and updated recalls and alerts by category.